TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved managem...
Main Authors: | Donald Freudenstein, Cassandra Litchfield, Franco Caramia, Gavin Wright, Benjamin J. Solomon, David Ball, Simon P. Keam, Paul Neeson, Ygal Haupt, Sue Haupt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/6/1535 |
Similar Items
-
Females and Males Show Differences in Early-Stage Transcriptomic Biomarkers of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
by: Quewang Liu, et al.
Published: (2021-02-01) -
Establishing the Link between X-Chromosome Aberrations and <i>TP53</i> Status, with Breast Cancer Patient Outcomes
by: Franco Caramia, et al.
Published: (2023-09-01) -
TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
by: Jiangyong Yu, et al.
Published: (2022-07-01) -
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer
by: Zeguo Sun, et al.
Published: (2022-07-01) -
Differential Expression of AP-2 Transcription Factors Family in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma—A Bioinformatics Study
by: Dagmara Szmajda-Krygier, et al.
Published: (2023-02-01)